Owen O'Connor, MD, PhD

Owen O&rsquo;Connor, MD, PhD, director of the Center for Lymphoid Malignancies at New York-Presbyterian Hospital, discusses the possibility of using chimeric antigen receptor (CAR) T-cell therapies for the treatment of patients with mantle cell lymphoma (MCL). This can be tricky for a number of reasons, but O&rsquo;Connor is hopeful that there are treatment regimens for this patient population that can work.

With expression of CD19 in MCL, there is some promise in the treatment landscape for CAR T-cells. Some early studies are showing promising observations for this, but researchers need to be aware of the risks and toxicities, O&rsquo;Connor says. Since MCL tends to be a highly drug-resistant disease as well as incredibly aggressive, researchers need to focus on what patients they are enrolling and if they have a chance of benefiting from CAR T-cells.

Videos

CAR T-Cells in the Treatment Landscape of Mantle Cell Lymphoma

Owen O&#39;Connor, MD, PhD, professor of medicine and Experimental Therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses the agents approved by the FDA for the treatment of mantle cell lymphoma (MCL), including acalabrutinib (Calquence) and bortezomib (Velcade).

Owen O'Connor, MD, PhD | Authors

Articles

CAR T-Cells in the Treatment Landscape of Mantle Cell Lymphoma

FDA-Approved Agents for the Treatment of MCL